Barbara Gayle Duncan Sells 147 Shares of Intercept Pharmaceuticals Inc. (ICPT) Stock
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CAO Barbara Gayle Duncan sold 147 shares of the stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $163.20, for a total value of $23,990.40. Following the completion of the sale, the chief accounting officer now directly owns 30,661 shares of the company’s stock, valued at $5,003,875.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 153.51 on Friday. The stock’s market cap is $3.80 billion. The stock has a 50 day moving average price of $158.07 and a 200 day moving average price of $150.46. Intercept Pharmaceuticals Inc. has a 12-month low of $89.76 and a 12-month high of $217.99.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, topping the consensus estimate of ($3.69) by $0.55. The firm earned $5.52 million during the quarter, compared to analyst estimates of $1.72 million. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. Intercept Pharmaceuticals’s revenue was up 1140.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.99) EPS. On average, analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.31) earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of Intercept Pharmaceuticals by 6.5% in the third quarter. BNP Paribas Arbitrage SA now owns 4,368 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 267 shares during the last quarter. Macquarie Group Ltd. increased its position in Intercept Pharmaceuticals by 129.1% in the second quarter. Macquarie Group Ltd. now owns 22,690 shares of the biopharmaceutical company’s stock valued at $3,237,000 after buying an additional 12,788 shares during the period. Nomura Holdings Inc. bought a new position in Intercept Pharmaceuticals during the second quarter valued at approximately $384,000. Schwab Charles Investment Management Inc. increased its position in Intercept Pharmaceuticals by 19.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 56,429 shares of the biopharmaceutical company’s stock valued at $8,052,000 after buying an additional 9,112 shares during the period. Finally, Amalgamated Bank increased its position in Intercept Pharmaceuticals by 39.0% in the second quarter. Amalgamated Bank now owns 2,619 shares of the biopharmaceutical company’s stock valued at $413,000 after buying an additional 735 shares during the period. Hedge funds and other institutional investors own 81.86% of the company’s stock.
Several analysts have recently commented on the company. Wedbush reissued an “outperform” rating and issued a $239.00 price objective on shares of Intercept Pharmaceuticals in a research note on Monday, July 25th. Robert W. Baird reissued an “outperform” rating and issued a $332.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, June 15th. Credit Suisse Group AG reissued a “buy” rating and issued a $200.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, August 5th. Vetr downgraded Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $81.50 price objective for the company. in a research note on Monday, August 8th. Finally, Oppenheimer Holdings Inc. lowered their price objective on Intercept Pharmaceuticals from $265.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, August 5th. Five equities research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $177.67.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.